https://www.selleckchem.com/pr....oducts/Perifosine.ht
in stratifying patients with T1G3 who need to proceed to early radical cystectomy versus conservative treatment. Bladder-sparing chemoradiation therapy is a definitive first-line treatment option for muscle-invasive bladder cancer. Randomized trials have demonstrated that the addition of neoadjuvant chemotherapy to radical cystectomy or radiation monotherapy results in a survival benefit. Whether neoadjuvant chemotherapy improves outcomes when used with definitive chemoradiation is unknown. We identified 2566 patients in the National
Like
Comment
Share
